0QNO Stock Overview Supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Lonza Group AG Competitors Price History & Performance
Summary of share price highs, lows and changes for Lonza Group Historical stock prices Current Share Price CHF 531.88 52 Week High CHF 589.00 52 Week Low CHF 339.10 Beta 0.64 1 Month Change 1.07% 3 Month Change -0.36% 1 Year Change 51.77% 3 Year Change -30.35% 5 Year Change 50.12% Change since IPO 526.55%
Recent News & Updates
Lonza Group AG to Report First Half, 2025 Results on Jul 23, 2025 Oct 30
Lonza Group AG Provides Earnings Guidance for Full Year 2024 Oct 24 Lonza Group AG (SWX:LONN) completed the acquisition of Genentech Manufacturing Facility in Vacaville, California from Roche Holding AG (SWX:ROG). Oct 02
First half 2024 earnings released: EPS: CHF4.61 (vs CHF5.54 in 1H 2023) Jul 28
Lonza Group AG to Report Fiscal Year 2024 Results on Jan 30, 2025 Jul 26
Now 24% overvalued after recent price rise Jul 26 See more updates
Lonza Group AG to Report First Half, 2025 Results on Jul 23, 2025 Oct 30
Lonza Group AG Provides Earnings Guidance for Full Year 2024 Oct 24 Lonza Group AG (SWX:LONN) completed the acquisition of Genentech Manufacturing Facility in Vacaville, California from Roche Holding AG (SWX:ROG). Oct 02
First half 2024 earnings released: EPS: CHF4.61 (vs CHF5.54 in 1H 2023) Jul 28
Lonza Group AG to Report Fiscal Year 2024 Results on Jan 30, 2025 Jul 26
Now 24% overvalued after recent price rise Jul 26
Now 22% undervalued May 29
Now 22% undervalued May 15 Lonza Group AG Approves Cash Dividend, Payable on May 15, 2024
Now 20% undervalued Apr 19
Full year 2023 earnings released: EPS: CHF8.88 (vs CHF16.37 in FY 2022) Apr 04
Dividend of CHF2.00 announced Apr 04
New minor risk - Earnings quality Apr 04
Lonza Group AG Announces Chief Executive Officer Changes Apr 02 Lonza Group AG to Report First Half, 2024 Results on Jul 25, 2024
Full year 2023 earnings released: EPS: CHF8.88 (vs CHF16.37 in FY 2022) Jan 26
Lonza Group AG to Report Fiscal Year 2023 Results on Jan 26, 2024 Jan 12
Lonza Group AG, Annual General Meeting, May 08, 2024 Jan 06
Investor sentiment deteriorates as stock falls 21% Oct 18
Lonza Group AG Provides Sales Guidance for the Year 2023 Sep 21
Lonza Group AG Announces CEO Changes Sep 18
First half 2023 earnings released: EPS: CHF5.54 (vs CHF6.67 in 1H 2022) Jul 23
Lonza Group AG (SWX:LONN) acquired Synaffix BV. Jun 02
Lonza Group AG (SWX:LONN) acquired Synaffix BV. Jun 01
Lonza Group AG Reiterates Sales Guidance for the Years 2023 May 11
Upcoming dividend of CHF3.50 per share at 0.6% yield May 02
Full year 2022 earnings released: EPS: CHF16.37 (vs CHF9.08 in FY 2021) Mar 29
Lonza Group AG to Report First Half, 2023 Results on Jul 21, 2023 Jan 27
Full year 2022 earnings released: EPS: CHF16.37 (vs CHF9.08 in FY 2021) Jan 26
Lonza Group AG Provides Earnings Guidance for the Year 2023 Jan 26
Lonza Group AG (SWX:LONN) announces an Equity Buyback for CHF 2,000 million worth of its shares. Jan 25 Lonza Group AG, Annual General Meeting, May 05, 2023
Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division, Effective from November 1, 2022 Sep 13
First half 2022 earnings released Jul 22
Lonza Group AG Reconfirms Sales Guidance for the Years 2022 and 2024 Jul 22
Lonza Group Announces Management Changes, Effective August 1, 2022 Jul 02
Upcoming dividend of CHF3.00 per share May 02
Insufficient new directors Apr 27
Sigma-Aldrich Corporation acquired Modular Automated Sampling Technology Platform of Lonza Group AG. Apr 07
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Jan 27
Lonza Group Ltd. Announces Sales Guidance for the Full-Year 2022 Jan 27
Insufficient new directors Dec 06
Lonza and Triumvira Immunologics Announces First Patient with HER2-overexpressing Cancer Dosed with TAC-T Cell Therapy Using the Lonza Cocoon Platform Sep 23
Lonza Group Ltd Provides Earnings Guidance for the Year 2021 Jul 24
First half 2021 earnings released: EPS CHF3.51 (vs CHF5.94 in 1H 2020) Jul 24
Lonza Group Ltd Approves Dividend, Payable Starting from May 12, 2021 May 08
Upcoming dividend of CHF3.00 per share May 04
Altimmune, Inc. Expands AdCOVID™ Manufacturing Collaboration with Lonza Mar 13
New 90-day high: CHF609 Feb 15 NextPharma Technologies Holding Limited signed an agreement to acquire Lonza's Ploermel (FR) and Edinburgh (UK) sites from Lonza Group Ltd (SWX:LONN).
Capricor Collaborates with Lonza for the Development of Cap-1002, Its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications Jan 13
Arbor Biotechnologies and Lonza Enter into Gene Editing Technology Licensing Deal Dec 25
Aurinia Pharmaceuticals Inc. and Lonza Group Ltd Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity Dec 17
Lonza Announces Customer-Dedicated Suites for Commercialization of Bioconjugates Dec 03
Lonza and Be The Match BioTherapies Partner to Expand Vein-to-Vein Cell and Gene Therapy Supply Chain Network Nov 20
Altimmune, Inc. Adds Lonza as a Manufacturing Partner for Supply of AdCOVID its Single-Dose Intranasal Vaccine Candidate for COVID-19 Nov 11
New 90-day high: CHF624 Nov 05
Lonza Group Ltd Announces Management Changes Nov 04
New 90-day high: CHF597 Oct 17
Lonza Reportedly Starts Disposal of Specialty Ingredients Unit Oct 02
New 90-day high - CHF579 Aug 03 Shareholder Returns 0QNO GB Life Sciences GB Market 7D -1.8% -13.4% -1.9% 1Y 51.8% -31.5% 2.6%
See full shareholder returns
Return vs Market: 0QNO exceeded the UK Market which returned 2.6% over the past year.
Price Volatility Is 0QNO's price volatile compared to industry and market? 0QNO volatility 0QNO Average Weekly Movement 3.6% Life Sciences Industry Average Movement 7.5% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.7% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0QNO has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0QNO's weekly volatility (4%) has been stable over the past year.
About the Company Founded Employees CEO Website 1897 17,834 Wolfgang Wienand www.lonza.com
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing.
Show more Lonza Group AG Fundamentals Summary How do Lonza Group's earnings and revenue compare to its market cap? 0QNO fundamental statistics Market cap CHF 38.45b Earnings (TTM ) CHF 573.00m Revenue (TTM ) CHF 6.70b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0QNO income statement (TTM ) Revenue CHF 6.70b Cost of Revenue CHF 4.29b Gross Profit CHF 2.41b Other Expenses CHF 1.84b Earnings CHF 573.00m
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Jan 29, 2025
Earnings per share (EPS) 7.93 Gross Margin 36.01% Net Profit Margin 8.56% Debt/Equity Ratio 40.3%
How did 0QNO perform over the long term?
See historical performance and comparison Dividends
0.8% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/24 13:50 End of Day Share Price 2024/12/23 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Lonza Group AG is covered by 50 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Martin Schnee AlphaValue Volker Bosse Baader Helvea Equity Research Charles Pitman-King Barclays
Show 47 more analysts 
